Side effects
Wegovy pill side effects vs the injection
Mostly the same list at the same rates. The label says the tablet trial found adverse reactions similar in type and frequency to the injection table, where nausea leads at 44 percent. Two things are specific to the tablet: skin sensations, reported by 5 percent on 25 mg tablets, and a wider spread in how much drug each person absorbs.
DM, the one who read the label
Sources checked Sep 28, 2026
Published Oct 23, 2026
Updated Sep 28, 2026 · 2 min read
The short answer
Mostly the same list at the same rates. The label says the tablet trial found adverse reactions similar in type and frequency to the injection table, where nausea leads at 44 percent. Two things are specific to the tablet: skin sensations, reported by 5 percent on 25 mg tablets, and a wider spread in how much drug each person absorbs.
What the label says
The tablet's safety was studied in its own trial, 204 adults on 25 mg for up to 64 weeks. The label sums it up in one sentence and sends the reader to the injection's table.
From the labelIn the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3.
Table 3 is the injection's: nausea 44 percent against 16 on placebo, diarrhea 30 against 16, vomiting 24 against 6, constipation 24 against 11, abdominal pain 20 against 10, headache 14 against 10, fatigue 11 against 5, dyspepsia 9 against 3, dizziness 8 against 4, reflux 5 against 3, hair loss 3 against 1.
In the tablet trial itself, 6.9 percent of people stopped for side effects against 5.9 percent on placebo, and stomach reactions were the reason in 3.4 percent against 2.
The two differences the label records
The first is on the skin. The label groups burning, tingling, sensitive and painful skin under dysesthesia. On the injection it is 2 percent. In the tablet trial, 5 percent of people on 25 mg reported it and nobody on placebo did.
The second is not a side effect but a spread. The tablet delivers about 1 to 2 percent of its dose, and how much depends on the morning. The label says concentrations on 25 mg tablets are comparable to the 2.4 mg injection with higher variability, and gives the ranges: 90 percent of tablet users between 27 and 186 nmol/L, against 51 to 110 on the injection.
Heart rate belongs to both: the label reports increases with the injection and says findings were similar with the tablets.
What people actually do
People who switched from the injection compare notes on two things: the stomach, which most find about the same, and the mornings, which are new. A minority describe the tablet as milder and a minority as rougher, and the label's sentence about variability covers both without contradiction.
The skin sensations surprise people because nobody warned them. Burning forearms, sensitive skin under a shirt, a lip that tingles: the label lists them, and they belong in the journal and at the next appointment.
Oolite's journal keeps side effects by day and by step, for whichever form the prescriber wrote, so the comparison at the appointment is on the screen rather than from memory.
Questions people ask
Is the pill gentler on the stomach than the injection?
Not by the label. It says the types and frequency of common adverse reactions in the tablet trial were similar to those listed for the injection. In the tablet trial, 3.4 percent stopped because of stomach reactions, versus 2 percent on placebo.
What are the skin sensations?
The label groups them as dysesthesia: burning, tingling, sensitive or painful skin. In the 25 mg tablet trial, 5 percent reported them and nobody on placebo did. In the injection table the figure is 2 percent.
Does the pill affect the heart rate too?
The label reports heart rate increases with the injection and says findings were similar in a trial with the tablets. It asks prescribers to monitor heart rate and patients to report palpitations.
Why would the pill vary more between people?
Because only about 1 to 2 percent of each tablet is absorbed, and that share depends on the morning. The label puts 90 percent of tablet users between 27 and 186 nmol/L, against 51 to 110 on the injection. Same middle, wider spread.
Sources
- Wegovy prescribing information, Novo Nordisk, §5.9, §6.1 (Table 3, Study 7, dysesthesia) and §12.3, revised 06/2026 · Tablet reactions similar to Table 3; 6.9 vs 5.9 percent discontinued; 3.4 vs 2 percent for GI; dysesthesia 5 percent on tablets, 2 percent on injection; heart rate findings similar; concentrations comparable with higher variability.
Sources checked Sep 28, 2026. This page is information, not medical advice: read the medical disclaimer, and talk to your prescriber or pharmacist about your own treatment.
Written by
DM, the one who read the label
I make Oolite. I read every label revision the day it comes out and rewrite these answers when they change.
How these pages are madeOolite
The GLP-1 tracker for the pill and the shot.
The 30 minute timer, your shot day, the level chart and the dose reminder, on iPhone, with Apple Watch to log. Free to download, then a 14-day free trial.
